Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ExonHit Therapeutics has obtained regulatory approval to initiate a Phase II clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease.
Subscribe to our email newsletter
This will be the first Phase II clinical trial for EHT 0202 and it will be a multi-center, double-blind trial, in which 135 patients will be randomized. The trial’s primary endpoint is the safety and tolerability of the product when it is administered orally for a three month period in conjunction with an acetylcholinesterase inhibitor, the most common therapy used to treat Alzheimer’s disease. The trial will also provide preliminary data on EHT 0202’s clinical efficacy, in particular regarding its effects on cognition and behaviour.
EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss.
Bruno Tocque, president of the management board of ExonHit, said: “We are delighted to initiate our Phase II clinical trial for EHT 0202. We also aim, through that study, to further illustrate the clinical utility of our blood-based diagnostic for Alzheimer’s disease. This milestone reflects ExonHit’s strategy, which is to provide therapeutic and diagnostic solutions in chronic diseases such as Alzheimer’s disease.”